TGF-β1 mediates sirolimus and cyclosporine a-induced alteration of barrier function in renal epithelial cells via a noncanonical ERK1/2 signaling pathway

American Journal of Physiology - Renal Physiology

Volumn 301, Issue 6, 2011, Pages

  Martin Martin, Natalia ^a   Slattery, Craig ^a   McMorrow, Tara ^a   Ryan, Michael P ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Claudin; Immunosuppressive drugs; Nephrotoxicity; Transepithelial electrical resistance

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CLAUDIN; CLAUDIN 1; CYCLOSPORIN A; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOTRANSFERASE; RAPAMYCIN; SD 208; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA1 RECEPTOR KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ELECTRIC RESISTANCE; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; GENE EXPRESSION REGULATION; KIDNEY EPITHELIUM; KIDNEY PROXIMAL TUBULE; NONHUMAN; ORGAN TRANSPLANTATION; PERMEABILITY BARRIER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SWINE; TIGHT JUNCTION;

EID: 82755162650     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00188.2010     Document Type: Article

References (38)

1. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with Image J. Biophotonics Int 11: 7, 36-42, 2004.
2. Akoolel S, Doller A, Babelova A, Tsalastra W, Moreth K, Schaefer L, Pfeilschifter J, Eberhardt W. Molecular mechanisms of TGF beta receptor-triggered signaling cascades rapidly induced by the calcineurin inhibitors cyclosporin A and FK506. J Immunol 181: 2831-2845, 2008.
3. Beltinger J, McKaig BC, Makh S, Stack WA, Hawkey CJ, Mahida YR. Human colonic subepithelial myofibroblasts modulate transepithelial resistance and secretory response. Am J Physiol Cell Physiol 277: C271-C279, 1999.
4. Bennett WM, Burdmann EA, Andoh TF, Houghton DC, Lindsley J, Elzinga LW. Nephrotoxicity of immunosuppressive drugs. Nephrol Dial Transplant 9, Suppl 4: 141-145, 1996.
5. Brook NR, Waller JR, Bicknell GR, Nicholson ML. Cyclosporine and rapamycin act in a synergistic and dose-dependent manner in a model of immunosuppressant-induced kidney damage. Transplant Proc 37: 837-838, 2005.
6. Cohen DJ, Loertscher R, Rubin MF, Tilney NL, Carpenter CB, Strom TB. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med 101: 667-682, 1984.
7. Damiao MJ, Bertocchi AP, Monteiro RM, Goncalves GM, Cenedeze MA, Feitoza CQ, Marques GD, Giannocco G, Mazzali M, Teixeira VP, Dos Reis MA, Pacheco-Silva A, Camara NO. The effects of rapamycin in the progression of renal fibrosis. Transplant Proc 39: 457-459, 2007.
8. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature 425: 577-584, 2003.
9. Dignass AU, Podolsky DK. Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta. Gastroenterology 105: 1323-1332, 1993.
10. Dodge IL, Demirci G, Strom TB, Li XC. Rapamycin induces transforming growth factor-beta production by lymphocytes. Transplantation 70: 1104-1106, 2000.
11. Feldman G, Kiely B, Martin N, Ryan G, McMorrow T, Ryan MP. Role for tgf-Beta in cyclosporine-induced modulation of renal epithelial barrier function. J Am Soc Nephrol 18: 1662-1671, 2007.
12. Gao R, Lu Y, Xin YP, Zhang XH, Wang J, Li YP. The effects of different immunosuppressants on chronic allograft nephropathy by affecting the transforming growth factor-beta and Smads signal pathways. Transplant Proc 38: 2154-2157, 2006.
13. Holm TM, Habashi JP, Doyle JJ, Bedja D, Chen Y, van Erp C, Lindsay ME, Kim D, Schoenhoff F, Cohn RD, Loeys BL, Thomas CJ, Patnaik S, Marugan JJ, Judge DP, Dietz HC. Noncanonical TGFß signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 332: 358-361, 2011.
14. Howe KL, Reardon C, Wang A, Nazli A, McKay DM. Transforming growth factor-beta regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia coli O157:H7-induced increased permeability. Am J Pathol 167: 1587-1597, 2005.
15. Hull RN, Cherry WR, Weaver GW. The origin and characteristics of a pig kidney cell strain, LLC-PK. In Vitro 12: 670-677, 1976.
16. Islam M, Burke JF, McGowan TA, Zhu Y, Dunn SR, McCue P, Kanalas J, Sharma K. Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Kidney Int 59: 498-506, 2001.
17. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 356: 194-202, 2000.
18. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 68: 1526-1532, 1999.
19. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 66: 1040-1046, 1998.
20. Khanna AK. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation 70: 690-694, 2000.
21. Khanna AK, Cairns VR, Becker CG, Hosenpud JD. Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine. Transplantation 67: 882-889, 1999.
22. Khanna AK, Plummer MS, Hilton G, Pieper GM, Ledbetter S. Anti-transforming growth factor antibody at low but not high doses limits cyclosporine-mediated nephrotoxicity without altering rat cardiac allograft survival: potential of therapeutic applications. Circulation 110: 3822-3829, 2004.
23. Langham RG, Egan MK, Dowling JP, Gilbert RE, Thomson NM. Transforming growth factor-beta1 and tumor growth factor-beta-inducible gene-H3 in nonrenal transplant cyclosporine nephropathy. Transplantation 72: 1826-1829, 2001.
24. Lee MK, Pardoux C, Hall MC, Lee PS, Warburton D, Qing J, Smith SM, Derynck R. TGF-beta activates Erk MAP kinase signaling through direct phosphorylation of ShcA. EMBO J 26: 3957-3967, 2007.
25. Lee S, Kim W, Kim DH, Moon SO, Jung YJ, Lee AS, Kang KP, Jang KY, Lee SY, Sung MJ, Koh GY, Park SK. Protective effect of COMPangiopoietin-1 on cyclosporine-induced renal injury in mice. Nephrol Dial Transplant 23: 2784-2794, 2008.
26. Ling H, Li X, Jha S, Wang W, Karetskaya L, Pratt B, Ledbetter S. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporine A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 14: 377-388, 2003.
27. Lloberas N, Torras J, Alperovich G, Cruzado JM, Gimenez-Bonafe P, Herrero-Fresneda I, Franquesa M, Rama I, Grinyo JM. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats. Nephrol Dial Transplant 23: 3111-3119, 2008.
28. Martin-Martin N, Ryan G, McMorrow T, Ryan MP. Sirolimus and cyclosporine A alter barrier function in renal proximal tubular cells through stimulation of ERK1/2 signaling and claudin-1 expression. Am J Physiol Renal Physiol 298: F672-F682, 2010.
29. Planchon SM, Martins CA, Guerrant RL, Roche JK. Regulation of intestinal epithelial barrier function by TGF-beta 1. Evidence for its role in abrogating the effect of a T cell cytokine. J Immunol 153: 5730-5739, 1994.
30. Shihab FS. Cyclosporine nephropathy: pathophysiology and clinical impact. Semin Nephrol 16: 536-547, 1996.
31. Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 65: 1262-1271, 2004.
32. Simmons RG, Abress L, Anderson CR. Quality of life after kidney transplantation. A prospective, randomized comparison of cyclosporine and conventional immunosuppressive therapy. Transplantation 45: 415-421, 1988.
33. Slattery C, Campbell E, McMorrow T, Ryan MP. Cyclosporine A-induced renal fibrosis: a role for epithelial-mesenchymal transition. Am J Pathol 167: 395-407, 2005.
34. Slattery C, Ryan MP, McMorrow T. Protein kinase C beta overexpression induces fibrotic effects in human proximal tubular epithelial cells. Int J Biochem Cell Biol 40: 2218-2229, 2008.
35. Swinford RD, Pascual M, Diamant D, Tang SS, Ingelfinger JR. Rapamycin increases transforming growth factor-beta mRNA expression in immortalized rat proximal renal tubular cells. Transplantation 73: 319-320, 2002.
36. Woo PL, Cha HH, Singer KL, Firestone GL. Antagonistic regulation of tight junction dynamics by glucocorticoids and transforming growth factor-beta in mouse mammary epithelial cells. J Biol Chem 271: 404-412, 1996.
37. Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 69: 2029-2036, 2006.
38. Yoo J, Nichols A, Mammen J, Calvo I, Song JC, Worrell RT, Matlin K, Matthews JB. Bryostatin-1 enhances barrier function in T84 epithelia through PKC-dependent regulation of tight junction proteins. Am J Physiol Cell Physiol 285: C300-C309, 2003.